Co-Diagnostics Signs Agreements to Sell $5.5M in Stock

Jan 31, 2019

|

NEW YORK (GenomeWeb) — Co-Diagnostics announced today that it has signed definitive agreements to sell $5.5 million in common stock to institutional investors through a registered direct offering.

According to Co-Diagnostics, the agreements call for the sale of roughly 3.9 million shares at $1.40 per share. The offering is expected to close on Monday. HC Wainwright is the exclusive placement agent for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

Delivering Precision Health: the Role of Molecular Diagnostics

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jul

23

Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.

Jul

25

Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

Jul

31

Featured Webinar

Considerations and Impact of Implementing Targeted NGS in Myeloid Malignancies

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Menu